Haemolytic anaemia following rituximab treatment in a patient with pemphigus vulgaris.
W W
WW
Li
X X
XX
Chen
J
J
Yu
Y
Y
Wang
D F
DF
Bu
P
P
Tu
D000328:Adult; D000743:Anemia, Hemolytic / Q000139:chemically induced*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D001372:Aza Compounds / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D024841:Fluoroquinolones; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D000077266:Moxifloxacin; D010392:Pemphigus / Q000150:complications / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D000069283:Rituximab
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001372:Aza Compounds; D003879:Dermatologic Agents; D024841:Fluoroquinolones; D007155:Immunologic Factors; D011804:Quinolines; D000069283:Rituximab; D011239:Prednisolone; D000077266:Moxifloxacin; D008727:Methotrexate